Facebook Twitter LinkedIn Google Plus RSS

Lupin opens manufacturing facility in Somerset; 80 hired with 50 more to come

By ,
Executives and officials cut the ribbon on Lupin's Somerset manufacturing facility.
Executives and officials cut the ribbon on Lupin's Somerset manufacturing facility. - ()

Mumbai-based pharmaceutical manufacturer Lupin recently hosted U.S. Rep. Bonnie Watson Coleman and Indian Consul General to the United States Riva Ganguly Das at the ribbon-cutting ceremony of its first U.S. manufacturing facility, in Somerset.

“This expansion was a tenfold expansion in capacity at the Somerset site and was part of a plan to meet the demand for affordable medicine in the U.S.,” Vinita Gupta, CEO of Lupin, said. “We are as a company are very committed to meet the need; especially today, there is a big need to bring affordable medicines to the U.S. markets for patients, providers, government and other stakeholders.”

The pharmaceutical firm will manufacture generic and branded products out of its 150,000-square-foot facility. The firm shipped its first product from Somerset in January of this year. The firm has added 80 jobs to support its operations and expects to hire at least 50 more employees.

“We have gained a strong manufacturing foothold with our Somerset manufacturing facility,” Gupta said. “We’ve been able to enter areas like controlled substances and women’s health specialty. And, most importantly, we’ve been able to bring a skilled team of (research and development) and manufacturing experts into our organization.”

Lupin’s move was made possible after the company made an $880 million purchase of Gavis Pharmaceuticals and Novel Laboratories, and invested an additional $20 million in construction.

“Lupin continues to grow,” Lupin Somerset’s president, Kurt Nielsen, said. “About 3.5 billion standard units of product are shipped out of this facility. We’ll be north of 4.5 billion at the end of this next fiscal year.”

As it stands, Lupin manufactures 150 different products — most of which are generic drugs — out of Somerset. Nielsen said the company hopes to have up to a 50 percent increase in the number of products it manufactures in the next year.

“With this expansion, Lupin is not only putting more residents of our district to work, they are focusing on making affordable medicine for patients worldwide,” Watson Coleman said. “There is no better place in the world to make a significant investment in the biopharmaceutical and science industry than right here.”

Nielsen said Lupin hopes to add an additional 40,000 square feet of distribution space to its Somerset campus. And while the firm did not seek any state or local incentives, Lupin will seek help from the Economic Development Authority on its next expansion.

“The Somerset acquisition for us was a strategic investment to establish a deeper presence in the U.S.,” Gupta said. “To gain access to technology capabilities that complement ours and to be able to gain scientific and manufacturing team that complements ours out of India.”

More From This Industry

Mario Marroquin

Mario Marroquin

Mario Marroquin covers real estate. A native of El Salvador, Mario is bilingual in English and Spanish. He graduated from Penn State University and worked in Pennsylvania before moving to New Jersey. His email is mariom@njbiz.com.

Leave a Comment


Please note: All comments will be reviewed and may take up to 24 hours to appear on the site.

Post Comment
View Comment Policy